HMPL 295
Alternative Names: HMPL-295; HMPL-295S1Latest Information Update: 28 Jun 2024
At a glance
- Originator Hutchison MediPharma
- Developer HUTCHMED
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China
- 31 May 2024 Phase I development is ongoing in Solid tumours (Late-stage disease) in China (PO) (NCT04908046)
- 31 May 2024 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)